Skip to search formSkip to main contentSkip to account menu

Anti-VEGFC Monoclonal Antibody VGX-100

Known as: VEGF-C mAb VGX-100, VGX-100 
A fully human monoclonal antibody directed against the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential… 
National Institutes of Health

Related topics

Related topics

1 relation
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Phase I study of VGX-100, an anti-VEGF-C monoclonal antibody, with or without bevacizumab, in patients (pts) with advanced solid tumors.
TPS2619 Background: The vascular endothelial growth factor C (VEGFEC) induces angiogenesis via activation of both VEGFRE2 and… 
2012
2012
36 Improved Inhibition of Tumor Growth by the Novel Monoclonal Antibody VGX-100 Targeting VEGF-C in Combination with VEGF-Receptor Tyrosine Kinase Inhibitors
2011
2011
Abstract LB-284: The novel therapeutic monoclonal antibody VGX-100 neutralises VEGF-C and inhibits tumor growth and metastasis in subcutaneous and orthotopic models of human cancer.
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Angiogenesis and lymphangiogenesis are important… 
2010
2010
Abstract 2442: VGX-100, a novel therapeutic monoclonal antibody targeting VEGF-C that inhibits tumor growth
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Angiogenesis and lymphangiogenesis are important… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)